Tag: record

SPOKANE, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.49 per share on the company’s common stock. The common stock dividend is payable September 15, 2025, to shareholders of record at the close of business on August 19, 2025.

FREEHOLD, NJ, Aug. 06, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH) reported Total Income for the quarter ended June 30, 2025 of $66.6 million as compared to $60.3 million for the quarter ended June 30, 2024, representing an increase of 10%. Net Income Attributable to Common Shareholders amounted to $2.5 million or $0.03 per diluted share for the quarter ended June 30, 2025 as compared to Net Income Attributable to Common Shareholders of $527,000 or $0.01 per diluted share for the quarter ended June 30, 2024. Normalized Funds from Operations Attributable to Common Shareholders (“Normalized FFO”), was $19.5 million or $0.23 per diluted share for the quarter ended June 30, 2025, as compared to $16.8 million or $0.23 per diluted share for the quarter ended June 30, 2024.

Allentown, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) --

CrossAmerica Partners LP Reports Second Quarter 2025 Results

Lead Plaintiff Deadline is September 30th

JACKSONVILLE, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers,” “Regency” or the “Company”) (NASDAQ: REG) announced today that the Company’s Board of Directors (the “Board”) declared quarterly cash dividends on Regency’s common stock, Series A preferred stock, and Series B preferred stock.

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network^® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE^®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.